81 FR 52451 - National Institute on Alcohol Abuse and Alcoholism, Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 152 (August 8, 2016)

Page Range		52451-52452
FR Document		2016-18688

Federal Register, Volume 81 Issue 152 (Monday, August 8, 2016)

[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Pages 52451-52452]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-18688]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Alcohol Abuse and Alcoholism, Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Alcohol Abuse and 
Alcoholism Initial Review Group; Biomedical Research Review 
Subcommittee.
    Date: October 18, 2016.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Alcohol Abuse and Alcoholism, 
National Institutes of Health, Conference Room 3002-3004, 5635 
Fishers Lane, Rockville, MD 20852.
    Contact Person: Philippe Marmillot, Ph.D., Scientific Review 
Officer, National Institute on Alcohol Abuse and Alcoholism, 
National Institutes of Health, 5635 Fishers Lane, Room

[[Page 52452]]

2019, Bethesda, MD 20892, 301-443-2861, [email protected].

    Name of Committee: National Institute on Alcohol Abuse and 
Alcoholism Initial Review Group; Neuroscience Review Subcommittee.
    Date: October 27, 2016.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Alcohol Abuse and Alcoholism, 
National Institutes of Health, Terrace Level Conference Room 508-
509, 5635 Fishers Lane, Rockville, MD 20852.
    Contact Person: Beata Buzas, Ph.D., Scientific Review Officer, 
National Institute On Alcohol Abuse and Alcoholism, National 
Institutes of Health, 5635 Fishers Lane, Rm. 2081, Rockville, MD 
20852, 301-443-0800, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, 
Alcohol Research Career Development Awards for Scientists and 
Clinicians; 93.272, Alcohol National Research Service Awards for 
Research Training; 93.273, Alcohol Research Programs; 93.891, 
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical 
Research and Research Support Awards, National Institutes of Health, 
HHS)

    Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-18688 Filed 8-5-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices 52451

Administrative Operations (RV21); including Freedom of Information Act evaluates the Bureau’s organizational
replace in their entirety. requests. and staff development, and staff training
activities inclusive of guiding action
Office of the Associate Administrator Office of Operations and Management
steps addressing annual Employee
(RV) (RV2)
Viewpoint Survey results; and (13)
The Office of the Associate The Office of Operations and coordinates the development and
Administrator provides leadership and Management provides expertise distribution of all Bureau
direction for the HIV/AIDS programs guidance, leadership, and support in the communication activities, materials and
areas of general administration, fiscal products internally and externally.
and activities of the Bureau and
operations, and contract administration.
oversees its relationship with other Delegations of Authority
The Office of Operations and
national health programs. Specifically:
Management is responsible for All delegations of authority and re-
(1) promotes the implementation of the
providing direction on all budgetary, delegations of authority made to HRSA
National HIV/AIDS Strategy within the
administrative, human resources, officials that were in effect immediately
Agency and among Agency-funded
operations, facility management and prior to this reorganization, and that are
programs; (2) coordinates the
contracting functions for the HIV/AIDS consistent with this reorganization,
formulation of an overall strategy and
Bureau. The Office also oversees and shall continue in effect pending further
policy for programs established by Title
coordinates all Bureau program integrity re-delegation.
XXVI of the PHS Act as amended by the activities.
Ryan White HIV/AIDS Treatment This reorganization is effective upon
Extension Act of 2009, P.L. 111–87; (3) Division of Administrative Operations date of signature.
coordinates the internal functions of the (RV21) Dated: August 1, 2016.
Bureau and its relationships with other The Division of Administrative James Macrae,
Agency Bureaus and Offices; (4) Operations is responsible for the Acting Administrator.
establishes HIV/AIDS program administrative, human resources [FR Doc. 2016–18730 Filed 8–5–16; 8:45 am]
objectives, alternatives, and policy operations, facility management and
BILLING CODE 4165–15–P
positions consistent with broad contracting functions for the Bureau.
Administration guidelines; (5) provides Specifically, these functions are carried
leadership for and oversight of the out in the Administrative Services and DEPARTMENT OF HEALTH AND
Bureau’s budgetary development and Contracting Services Team. HUMAN SERVICES
implementation processes; (6) provides
clinical leadership to Ryan White- Office of Program Support (RV3)
National Institutes of Health
funded programs and global HIV/AIDS The Office of Program Support
programs; (7) oversees the provides expertise, guidance, National Institute on Alcohol Abuse
implementation of the Global HIV/AIDS leadership, and support in the areas of and Alcoholism, Notice of Closed
Program as part of the President’s organizational development, Meetings
Emergency Plan for AIDS Relief; (8) communications, grantee oversight, and
serves as a principal contact and advisor customer service to support program Pursuant to section 10(d) of the
to the Department and other parties on implementation. Specifically, the Office Federal Advisory Committee Act, as
matters pertaining to the planning and of Program Support: (1) enhances the amended (5 U.S.C. App.), notice is
development of HIV/AIDS-related coordination of program support, grants hereby given of the following meetings.
health delivery systems; (9) reviews management, and technical assistance The meetings will be closed to the
HIV/AIDS related program activities to across the entire Bureau; (2) plans, public in accordance with the
determine their consistency with implements and evaluates HAB staff provisions set forth in sections
established policies; (10) develops and development and education to enable 552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
oversees operating policies and employees to meet the mission of the as amended. The grant applications and
procedures for the Bureau; (11) oversees Bureau; (3) streamlines the discussions could disclose
and directs the planning, communications, clearance activities confidential trade secrets or commercial
implementation, and evaluation of and development of consistent, quality property such as patentable material,
special studies related to HIV/AIDS and presentations; (4) improves the Bureau’s and personal information concerning
public health within the Bureau; (12) external facing communication efforts; individuals associated with the grant
prioritizes technical assistance needs in (5) facilitates transparency in sharing applications, the disclosure of which
consultation with each division/office; the Bureau’s data using internal and would constitute a clearly unwarranted
(13) plans, implements, and evaluates external resources; (6) provides invasion of personal privacy.
the Bureau’s national technical leadership for and oversees Bureau’s
Name of Committee: National Institute on
assistance resource training center Web grants processes; (7) coordinates the Alcohol Abuse and Alcoholism Initial
site and other distance learning grants liaison activities; (8) supports Review Group; Biomedical Research Review
modalities; (14) represents the Agency grantee oversight and improves Subcommittee.
in HIV/AIDS related conferences, customer service and technical Date: October 18, 2016.
consultations, and meetings with other assistance to grantees; (9) serves as the Time: 8 a.m. to 5 p.m.
Operating Divisions, Office of the Bureau’s primary liaison with the Office Agenda: To review and evaluate grant
Assistant Secretary for Health, the of Federal Assistance Management; (10) applications.
mstockstill on DSK3G9T082PROD with NOTICES

Department of State, and the White supports systems development to Place: National Institute of Alcohol Abuse
House; and (15) oversees Bureau improve program efficiencies and and Alcoholism, National Institutes of
Health, Conference Room 3002–3004, 5635
Executive Secretariat functions and management; (11) provides support with Fishers Lane, Rockville, MD 20852.
coordinates HRSA responses and the implementation of staff Contact Person: Philippe Marmillot, Ph.D.,
comments on HIV/AIDS-related reports, development, organizational Scientific Review Officer, National Institute
position papers, guidance documents, development and training activities; (12) on Alcohol Abuse and Alcoholism, National
correspondence, and related issues, plans, develops, implements and Institutes of Health, 5635 Fishers Lane, Room

VerDate Sep<11>2014 22:23 Aug 05, 2016 Jkt 238001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\08AUN1.SGM 08AUN1

52452 Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices

2019, Bethesda, MD 20892, 301–443–2861, development research collaborations, Publications: 1. Lu X., et al., 2015
marmillotp@mail.nih.gov. and copies of the U.S. patent PLoS One 2015 Oct 14;10(10) PMID:
Name of Committee: National Institute on applications listed below may be 26466095.
Alcohol Abuse and Alcoholism Initial obtained by contacting: Attn. Invention Contact Information: Requests for
Review Group; Neuroscience Review Development and Marketing Unit, copies of the patent application or
Subcommittee. Technology Transfer Center, National inquiries about licensing, research
Date: October 27, 2016. collaborations, and co-development
Time: 8:30 a.m. to 5 p.m.
Cancer Institute, 9609 Medical Center
Agenda: To review and evaluate grant Drive, Mail Stop 9702, Rockville, MD, opportunities should be sent to John D.
applications. 20850–9702, Tel. 240–276–5515 or Hewes, Ph.D., email: john.hewes@
Place: National Institute on Alcohol Abuse email ncitechtransfer@mail.nih.gov. A nih.gov.
and Alcoholism, National Institutes of signed Confidential Disclosure Dated: July 26, 2016.
Health, Terrace Level Conference Room 508– Agreement may be required to receive John D. Hewes,
509, 5635 Fishers Lane, Rockville, MD 20852. copies of the patent applications. Technology Transfer Specialist, Technology
Contact Person: Beata Buzas, Ph.D.,
SUPPLEMENTARY INFORMATION: Transfer Center, National Cancer Institute.
Scientific Review Officer, National Institute
On Alcohol Abuse and Alcoholism, National Technology description follows. [FR Doc. 2016–18689 Filed 8–5–16; 8:45 am]
Institutes of Health, 5635 Fishers Lane, Rm. Title of invention: Synthetic Human- BILLING CODE 4140–01–P
2081, Rockville, MD 20852, 301–443–0800, Derived Peptides and Peptidomimetics
bbuzas@mail.nih.gov. for Cancer Therapeutics
(Catalogue of Federal Domestic Assistance Keywords: Rpn13, selective DEPARTMENT OF HEALTH AND
Program Nos. 93.271, Alcohol Research proteasome inhibitor, proteasome HUMAN SERVICES
Career Development Awards for Scientists ubiquitin receptors, (competition:
and Clinicians; 93.272, Alcohol National carfilzomib and bortezomib too toxic, National Institutes of Health
Research Service Awards for Research resistance developed), solid tumors,
Training; 93.273, Alcohol Research Programs; National Cancer Institute; Notice of
hematological cancer, HPV associated
93.891, Alcohol Research Center Grants; Meeting
93.701, ARRA Related Biomedical Research
cancer, ovarian cancer, prostate cancer,
and Research Support Awards, National gastric cancer, breast cancer, or Pursuant to section 10(d) of the
Institutes of Health, HHS) colorectal cancer Federal Advisory Committee Act, as
Description of Technology: FDA amended (5 U.S.C. App. 2), notice is
Dated: August 2, 2016.
approved 26S proteasome inhibitors, hereby given of the meeting of the
Melanie J. Gray, such as carfilzomib and bortezomib National Cancer Advisory Board
Program Analyst, Office of Federal Advisory (Velcade®) have proven to be effective at
Committee Policy.
(NCAB).
treating hematologic cancers. However, The meeting will be open to the
[FR Doc. 2016–18688 Filed 8–5–16; 8:45 am] resistance to these agents as well as public as indicated below, with
BILLING CODE 4140–01–P their toxicity have raised concerns and attendance limited to space available.
highlight the need for new 26S Individuals who plan to attend and
proteasome inhibitors. need special assistance, such as sign
DEPARTMENT OF HEALTH AND Investigators at the NCI’s Structural language interpretation or other
HUMAN SERVICES Biophysics Laboratory have developed a reasonable accommodations, should
National Institutes of Health new class of proteasome inhibitors. notify the Contact Person listed below
They are hRpn2-derived peptides in advance of the meeting. The open
Government-Owned Inventions; capable of specifically targeting the Pru session will be videocast and can be
Availability for Licensing domain of hRpn13. Disruption of the accessed from the NIH Videocasting and
Rpn2/Rpn13 interaction inhibits Podcasting Web site (http://
AGENCY: National Institutes of Health, proteolysis by a mechanism that differs videocast.nih.gov).
Department of Health and Human from those of the approved proteasome A portion of the National Cancer
Services. inhibitors. Advisory Board meeting will be closed
ACTION: Notice. Potential Commercial Applications: to the public in accordance with the
• New class of proteasome inhibitors, provisions set forth in sections
SUMMARY: The invention listed below is targeting hRpn13 of the regulatory 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
owned by an agency of the U.S. particle. as amended. The grant applications and
Government and is available for Value Proposition: the discussions could disclose
licensing and/or co-development in the • Synergistic with, and more specific confidential trade secrets or commercial
U.S. in accordance with 35 U.S.C. 209 than, known proteasome inhibitors. property such as patentable material,
and 37 CFR part 404 to achieve • Alternate mechanism of action and personal information concerning
expeditious commercialization of compared to approved proteasome individuals associated with the grant
results of federally-funded research and inhibitors. applications, the disclosure of which
development. Foreign patent Development Stage: Discovery (Lead would constitute a clearly unwarranted
applications are filed on selected ID). invasion of personal privacy.
inventions to extend market coverage Inventor(s): Kylie J. Walters (NCI), Fen Name of Committee: National Cancer
for companies and may also be available Liu (NCI), and Xiuxiu Lu (NCI). Advisory Board.
for licensing and/or co-development. Intellectual Property: Open: September 7, 2016, 9:00 a.m. to
mstockstill on DSK3G9T082PROD with NOTICES

ADDRESSES: Invention Development and HHS Reference No. E–278–2015/0– 05:00 p.m.
Marketing Unit, Technology Transfer US–01. Agenda: Programs reports and
Center, National Cancer Institute, 9609 US Provisional Application 62/ presentations; business of the Board.
Medical Center Drive, Mail Stop 9702, Place: National Institutes of Health,
222,530 (HHS Reference No. E–278– Building 31, C-Wing, 6th Floor, Room 10,
Rockville, MD 20850–9702. 2015) filed September 23, 2015 entitled 9000 Rockville Pike, Bethesda, MD 20892.
FOR FURTHER INFORMATION CONTACT: ‘‘Human RPN2 Derived Peptides Useful Closed: September 7, 2016, 04:00 p.m. to
Information on licensing and co- For Treating Cancer’’. 05:00 p.m.

VerDate Sep<11>2014 22:23 Aug 05, 2016 Jkt 238001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\08AUN1.SGM 08AUN1

Document Created: 2016-08-06 03:08:18
Document Modified: 2016-08-06 03:08:18

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 18, 2016.
FR Citation		81 FR 52451

81 FR 52451 - National Institute on Alcohol Abuse and Alcoholism, Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 152 (August 8, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health